Literature DB >> 18806602

Biological therapies for atrial fibrillation.

Guy Amit1, Hao Qin, J Kevin Donahue.   

Abstract

Atrial fibrillation is a prominent cause of morbidity and mortality in developed countries. Current treatment strategies center on controlling heart rate while allowing fibrillation to persist or targeting fibrillation primarily and attempting to maintain sinus rhythm. Pharmacological therapies are largely successful for rate control, although mild toxicities are common. Rhythm control strategies are often unsuccessful, leaving patients in atrial fibrillation despite attempts to maintain sinus rhythm. This review will discuss novel biological strategies that are currently under development and may eventually have impact on the management of atrial fibrillation.

Entities:  

Mesh:

Year:  2008        PMID: 18806602     DOI: 10.1097/FJC.0b013e318182c8e0

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Fast and furious: new ways to think about, study and treat cardiac arrhythmias.

Authors:  Michael J Joyner; Stanley Nattel
Journal:  J Physiol       Date:  2009-04-01       Impact factor: 5.182

2.  MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation.

Authors:  Xiaobin Luo; Zhenwei Pan; Hongli Shan; Jiening Xiao; Xuelin Sun; Ning Wang; Huixian Lin; Ling Xiao; Ange Maguy; Xiao-Yan Qi; Yue Li; Xu Gao; Deli Dong; Yong Zhang; Yunlong Bai; Jing Ai; Lihua Sun; Hang Lu; Xiao-Yan Luo; Zhiguo Wang; Yanjie Lu; Baofeng Yang; Stanley Nattel
Journal:  J Clin Invest       Date:  2013-04-01       Impact factor: 14.808

Review 3.  Novel molecular targets for atrial fibrillation therapy.

Authors:  Dobromir Dobrev; Leif Carlsson; Stanley Nattel
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.